DUBAI, United Arab Emirates, July 14, 2026 (GLOBE NEWSWIRE) — $HOPPY, a community-driven cryptocurrency project inspired by Matt Furie’s early frog character Hoppy, is gaining attention as supporters work to bring the character’s history and cultural significance to a wider audience.

Created before Pepe the Frog became one of the internet’s most recognizable meme characters, Hoppy represents an earlier chapter in Furie’s creative work. The $HOPPY community is now building around that origin story, positioning the project as a connection between the formative years of internet culture and the expanding world of digital assets.

The project enters a meme-coin market where recognizable characters, community participation and compelling narratives often play a central role in attracting attention. Rather than introducing an entirely new mascot, $HOPPY draws upon an existing character and a story that predates the global rise of frog-based meme culture.

Supporters believe Hoppy’s history gives the project a distinct identity within a crowded sector. As new participants continue to discover the characters and artwork that shaped online culture, the community aims to establish Hoppy as an important part of that broader history.

The central message behind the project is straightforward: before Pepe became a worldwide internet phenomenon, there was Hoppy.

Through continued community growth, social media activity and awareness campaigns, $HOPPY intends to give the character an opportunity to reach audiences who may be unfamiliar with his origins.

For additional information and project updates, visit the official $HOPPY channels below.

About $HOPPY

$HOPPY is a community-driven cryptocurrency project inspired by Hoppy, an early frog character created by artist Matt Furie. The project brings together meme culture, digital communities and the historical appeal of one of Furie’s earlier characters.

Official Links

Website: https://hoppythefrog.fun/
X: https://x.com/HoppyTheFrogX
Telegram: https://t.me/HoppyFrogRH

CONTACT: Media Contact
EAC Marketing
Eac_marketing@hotmail.com

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. UKNewshour.com takes no editorial responsibility for the same.

Baltimore, MD, July 13, 2026 (GLOBE NEWSWIRE) — Most of the attention on artificial intelligence has gone to the technology itself. The models, the chatbots, the breakthroughs that seem to land every few weeks. But another number has started to catch the eye of people who watch corporate balance sheets for a living.

Over the first five months of 2026, companies tied to artificial intelligence took on roughly $236 billion in new debt.

Economist and former government advisor Jim Rickards has built a free presentation around that figure. His point is simple. How the AI boom is being paid for may end up telling us more than any product demo ever could.

Rickards notes that banks and private lenders keep inventing new ways to keep the money flowing, with fresh financing arrangements built specifically to fund AI projects. For him, all of it points to one question that rarely makes the headlines. Why does an industry this celebrated need to borrow this heavily?

An Industry Running on Borrowed Money

Powerful artificial intelligence is expensive to build. Companies are pouring money into the physical side of AI long before they can see what it will earn them. Warehouses full of computing hardware. Enormous amounts of electricity. The systems needed to tie it all together.

Most of that money goes out the door years ahead of any profit. Companies are betting demand will eventually catch up with the cost. Rickards thinks that bet is worth questioning. “Technology changes quickly,” he says in his presentation. “Balance sheets don’t.”

The Question Has Changed

For a long time, the excitement around AI was about what it could do. New tools, splashy partnerships, models that could write and reason. Investors are now asking something less glamorous. How much are these companies borrowing, how fast are the bills piling up, and when does any of it start paying for itself?

Rickards believes that change in focus is the real story. In his view, the debate is moving away from what AI can accomplish and toward whether the finances behind it hold up.

Raising Money Is Easy. Paying It Back Is Not.

Rickards is quick to say he isn’t betting against artificial intelligence. He thinks it could reshape the economy in real ways. What worries him is the distance between borrowing and earning.

Raising billions hasn’t been the hard part. Companies have shown they can do that. The harder part comes later, when the debt has to be repaid out of actual profits. Rickards believes many AI companies haven’t yet proven they can clear that second hurdle, and that investors may start demanding proof sooner than anyone expects.

A Date Worth Circling

Rickards keeps coming back to one point on the calendar. Around July 29, a wave of major AI companies will report their latest quarterly numbers. Investors will hear updated figures on spending, on financing, and on how much customers are actually paying.

For Rickards, those reports could show whether all that borrowed money is turning into real income, or whether the gap between the two is only getting wider.

Inside the Presentation

Rickards recently put out a free online presentation making the case that the money side of AI deserves as much attention as the technology.

He walks through the jump in AI borrowing, the reasons companies keep reaching for more capital, what the latest moves might mean for everyday investors, and why he thinks the next few weeks could test one of the market’s favorite stories.

You can watch the full presentation online HERE.

About Jim Rickards

Jim Rickards is an economist and investment strategist who has spent decades studying financial markets, monetary policy, and systemic risk. His career has included advisory work with the U.S. Treasury, the Department of Defense, and the U.S. intelligence community. Today he researches emerging financial trends and the major shifts that could shape the global economy.

Paradigm Press is one of the most widely read independent financial research publishers in the United States, rated 4.8 stars on Google across more than 1,900 reviews. Free from advertiser influence, Paradigm Press is committed to helping everyday Americans understand the forces shaping their wealth.

CONTACT: Derek Warren
Public Relations Manager
Paradigm Press Group
Email: dwarren@paradigmpressgroup.com

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. UKNewshour.com takes no editorial responsibility for the same.

JonesTrading Institutional Services LLC is acting as sole book-running manager for the offering. The Company has granted the underwriters a 45-day option to purchase up to an additional 3,000,000 units at the initial public offering price to cover over-allotments, if any.

The Company is led by Harsha Agadi, Chairman, Alan F. Hill, Chief Executive Officer and Bryan Turley, Chief Financial Officer.

The public offering is being made only by means of a prospectus. When available, copies of the prospectus relating to the offering may be obtained from: JonesTrading Institutional Services LLC, 325 Hudson St, 6th Floor New York, NY 10013, or by e-mail at ECM@jonestrading.com.

A registration statement relating to the securities was filed with, and declared effective by, the Securities and Exchange Commission (“SEC”) on July 13, 2026. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

FORWARD-LOOKING STATEMENTS

This press release contains statements that constitute “forward-looking statements,” including with respect to the proposed initial public offering and search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the “Risk Factors” section of the Company’s registration statement filed with the SEC and the preliminary prospectus included therein. Copies of these documents are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

About Jones Ventures INTL Acquisition1 Corp

Jones Ventures INTL Acquisition1 Corp is a newly organized blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. 

Media Contact:

Bryan Turley
bturley@jonestrading.com

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. UKNewshour.com takes no editorial responsibility for the same.

Elevate Marketing Solutions, a health and wellness marketing agency specializing in patient acquisition, has outlined its Facebook advertising framework for independent practices seeking a structured approach to generating new patient appointments. The framework combines pre-campaign market research, custom advertisement creation, dedicated landing pages, ongoing daily oversight, and integrated follow-up processes to direct outcomes toward scheduled appointments and measurable practice results rather than isolated engagement indicators.

Before launching any campaigns, the agency implements its Market Analysis Program to examine local market conditions, patient requirements, and competitive factors in the specific community served by each practice. This preparatory step provides a data-informed basis for campaign development and helps avoid misaligned advertising efforts. “A thorough understanding of the local market and patient dynamics forms the necessary foundation before any advertising activity begins,” said Dr. Kendall Price, Founder and CEO of Elevate Marketing Solutions. “This analysis helps align campaign efforts with actual opportunities available to the practice.”

Advertisements developed under the framework incorporate several coordinated elements intended to capture attention and prompt action. These include immediate local references to establish relevance for nearby residents, authentic visual content recorded directly from the clinic environment using standard smartphone methods, and structured offers designed to minimize initial barriers for prospective patients. Completed advertisements guide users to custom landing pages built specifically for the campaign, with content that addresses particular health concerns and maintains mobile accessibility for typical browsing habits. Practices have noted that such targeted pages facilitate smoother transitions from initial interest to appointment requests compared to general website navigation.

Campaign management occurs through daily reviews conducted by a United States-based team responsible for monitoring performance data, adjusting budget allocations, testing variations in creative content, and refining audience parameters as needed. This consistent oversight addresses the dynamic nature of social media advertising environments where audience responses and platform conditions can shift rapidly. Adjustments made on a frequent basis help maintain relevance and efficiency throughout the duration of active campaigns.

The framework extends beyond advertisement delivery to encompass structured follow-up mechanisms that support conversion of inquiries into confirmed appointments. These mechanisms combine automated messaging through text and email channels with human-assisted outreach, including responses to missed calls and access to bilingual support staff when appropriate. Speed of response receives particular attention because delays between initial contact and engagement can result in lost opportunities. All communication processes operate with attention to applicable privacy and compliance considerations common in health-related services. Integration of these follow-up components helps reduce instances where potential patients disengage prior to completing the booking process.

Measurement of framework effectiveness centers on the number of patients who attend appointments and the corresponding collections generated for participating practices. This patient-centered evaluation differs from approaches that emphasize intermediate indicators such as likes, shares, or raw lead volume alone. Documented outcomes from various implementations include one neuropathy care practice that recorded 22 new patients following a $1,500 advertising investment, with collections totaling $34,000. A separate general chiropractic practice observed 35 new patients from a $2,000 spend, producing $45,000 in collections. A regenerative medicine practice reported 18 new patients from a $3,500 investment, resulting in $85,000 collected. These instances illustrate the range of outcomes observed across different practice focuses and market conditions when the full framework operates as designed. “Success in these campaigns is ultimately determined by the patients who schedule and attend appointments, along with the financial outcomes for the practice,” said Dr. Kendall Price, Founder and CEO of Elevate Marketing Solutions. “The integration of creative, targeting, and follow-up processes supports consistent progress toward those measurable goals.”

The methodology applies across diverse practice types and community sizes, including smaller markets where consistent patient flow depends heavily on precise messaging, offer relevance, and reliable follow-through rather than broad market scale. It supports promotion of core chiropractic services as well as specialized offerings such as neuropathy care, shockwave therapy, spinal decompression, and prenatal or pediatric care. By connecting advertising activities directly to operational follow-up and appointment systems, the approach aims to create more predictable contributions to practice schedules and revenue streams.

Elevate Marketing Solutions was established by Dr. Kendall Price, a 2015 graduate of Life University who previously developed his own Aurora Chiropractic practice into a seven-figure operation within five years through coordinated online and in-person marketing techniques. The agency has provided support to more than 700 offices in the health and wellness field and has assisted over 100 practices in reaching collections above $1 million. Its work centers on constructing complete operational frameworks that link marketing activities to booked appointments, with services extending to website development, search engine optimization, and automation tools in addition to paid advertising. The organization maintains a focus on data-informed refinements and transparent communication regarding campaign performance with partner practices.

###

For more information about Elevate Marketing Solutions, contact the company here:

Elevate Marketing Solutions
Dr. Kendall Price
(813) 896-2772
admin@goelevatemarketing.com
16703 Early Riser Ave
Land O’ Lakes, FL 34638

CONTACT: Dr. Kendall Price

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. UKNewshour.com takes no editorial responsibility for the same.

As healthcare organizations continue refining their approaches to security, visitor management and controlled access have taken on heightened importance within healthcare security frameworks. These operational practices help facilities such as hospitals, clinics and surgery centers balance the need for safety with the requirement to remain accessible and supportive to patients and their families. Security professionals continue examining methods to integrate these elements into daily routines in ways that minimize disruption to clinical workflows and enhance overall site stability.

In contemporary medical environments, numerous factors influence security considerations. High volumes of individuals enter and exit throughout the day, including patients, family members, vendors and staff working across multiple shifts. Certain areas require restricted access to protect medical equipment, pharmaceuticals and confidential information. Emergency situations, ranging from internal incidents to external events, demand rapid yet organized responses. Staff protection during early morning or late evening hours represents another operational priority. These elements collectively shape how healthcare security programs are structured and executed on site.

Visitor management remains an important operational component because it directly affects both security posture and the daily experience within the facility. Practices typically include managing the flow of visitors at entry points, enforcing established visiting hours and, where appropriate, conducting security screening using equipment such as metal detectors or similar systems. The objective is to maintain control over who enters sensitive zones while offering clear guidance and assistance to those seeking care or supporting loved ones. When visitor management is handled effectively, it reduces confusion and supports a more orderly environment conducive to patient recovery and staff focus.

Jason vonReichbauer, MS, Vice President of Operations and Partner at STT Security Services, provides context on these dynamics. “In healthcare settings, visitor management requires officers to apply consistent procedures while remaining attentive to the needs of individuals who are often experiencing difficult circumstances. Controlled access to restricted areas must be maintained without creating unnecessary obstacles for legitimate visitors or interfering with the timely delivery of medical care. This balance depends on personnel who understand both security objectives and the operational realities of the facility.”

Such observations reflect the practical functioning of healthcare security programs. Officers generally perform regular patrols of premises to observe conditions and identify any irregularities. They monitor surveillance cameras and alarm systems to maintain awareness across the site. Access to buildings and specific zones is controlled according to facility policies, with verification processes applied as needed. When situations involving agitated individuals arise, officers follow established intervention protocols developed in coordination with healthcare staff. Emergency preparedness forms another layer, with personnel trained to assist in evacuations, provide crowd control and collaborate with law enforcement or other responders as circumstances require. These activities form core components of healthcare security efforts.

Protecting staff often involves practical measures such as providing escorts to parking facilities during off-peak hours and maintaining a visible presence that offers reassurance. Asset protection focuses on monitoring areas where medical equipment, supplies and pharmaceuticals are stored or dispensed, including pharmacies and laboratories, to prevent loss or unauthorized movement. Throughout these activities, a customer service orientation remains central. Officers provide directions, assist with wayfinding and parking inquiries, and interact in a manner that supports a welcoming atmosphere even as they uphold security standards.

Healthcare security programs achieve greater effectiveness when security personnel operate as an extension of the facility team rather than an isolated function. This requires site-specific procedures tailored to the layout, patient population and service mix of each location, whether a large hospital campus or a smaller outpatient center. Ongoing training in areas such as de-escalation, situational awareness and emergency response enables officers to adapt their approach while maintaining professional standards. Collaboration with clinical and administrative staff ensures that security activities align with care priorities and do not impede operational continuity.

Denise Robertson, MBA, Vice President of Finance and Human Resources and Partner at STT Security Services, underscores the personnel dimension. “The capability of security officers to contribute positively in healthcare environments stems from comprehensive preparation and a focus on interpersonal skills alongside technical responsibilities. When officers can communicate effectively and respond appropriately to varying situations, they support both the safety objectives and the broader goal of maintaining a supportive setting for patients, visitors and staff alike.”

These combined elements point to several implications for organizations seeking to strengthen their healthcare security posture. Integrated visitor management and access control practices can help reduce preventable incidents, support regulatory compliance efforts and allow medical professionals to concentrate on their core responsibilities. Facilities that invest in well-coordinated security operations often experience smoother daily functioning and greater confidence among those who work and receive care there. The emphasis remains on practical, adaptable measures rather than one-size-fits-all solutions, recognizing that each healthcare setting presents distinct requirements.

STT Security Services was founded in 1973 and is led by partners Denise Robertson, Jason vonReichbauer and Calvin Rusch. The employee-centered organization provides security services to healthcare facilities and clients in other industries across the United States, with an emphasis on trained personnel and protocol-driven responses tailored to client needs.

###

For more information about STT Security Services, contact the company here:

STT Security Services
Calvin Rusch
800-860-1788
info@sttsecurity.com
1600 N. Mission St.
Mt. Pleasant, MI 48858

CONTACT: Calvin Rusch

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. UKNewshour.com takes no editorial responsibility for the same.

U.S. launch of LEQEMBI IQLIK as an initiation dose planned for late August 2026

TOKYO and CAMBRIDGE, Mass., July 13, 2026 (GLOBE NEWSWIRE) — Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once-weekly lecanemab-irmb subcutaneous injection (brand name: LEQEMBI IQLIK^®) as an initiation dose for the treatment of early Alzheimer’s disease.

LEQEMBI IQLIK is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) dosing from the start of treatment. For initiation, the approved regimen is 500 mg given once weekly as two 250 mg injections, each delivered in approximately 15 seconds. LEQEMBI IQLIK may also be used for maintenance dosing at 360 mg once weekly after 18 months of IV or subcutaneous treatment. Throughout the entire treatment course – from initiation through maintenance – patients may receive LEQEMBI either as IV infusion or as subcutaneous (SC) injection with LEQEMBI IQLIK. Patients may also switch from IV to SC administration, or vice versa, providing greater convenience and flexibility in LEQEMBI administration.

LEQEMBI is indicated in the United States for adults with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease, collectively referred to as early Alzheimer’s disease. MCI due to AD is the earliest symptomatic stage of Alzheimer’s disease and can appear with subtle symptoms such as forgetfulness, confusion, or feeling at a loss for words.

Clinical Data Supporting FDA Approval of Subcutaneous Initiation Dosing

The FDA approval of LEQEMBI IQLIK as an initiation dose is supported by a comprehensive clinical data package evaluating SC administration of lecanemab across multiple studies and a range of dosing regimens. Sub-studies within the Phase 3 Clarity AD long-term extension (LTE), following the 18-month core study in individuals with early Alzheimer’s disease, showed:

• Once-weekly subcutaneous administration achieved exposure equivalent to intravenous dosing, supporting similar clinical (efficacy) and biomarker (amyloid removal) benefits.
• The rate of exposure-related adverse events such as ARIA-E with SC administration is expected to be comparable with IV administration. There was no increase in isolated ARIA-H (i.e., ARIA-H in patients who did not also experience ARIA-E) for LEQEMBI compared to placebo. 
• The overall safety profile of SC administration was generally similar to intravenous administration. Injection-related reactions were observed with subcutaneous LEQEMBI, most of which were localized, while systemic reactions were less frequently observed.

“The approval of LEQEMBI IQLIK for initiation dosing marks a new era of Alzheimer’s treatments,” said Howard Fillit, MD, Co-Founder and Chief Science Officer Emeritus of the Alzheimer’s Drug Discovery Foundation (ADDF). “For the first time, patients and their care partners have meaningful choice in how anti-amyloid treatment is delivered. As treatment approaches continue to expand, innovations in drug delivery will play a critical role in improving access to therapies, supporting the investigation of potential combination treatments, and advancing a precision medicine approach to Alzheimer’s care.”

Expanding Treatment Flexibility Across the Alzheimer’s Disease Care Pathway
The approval of LEQEMBI IQLIK as a subcutaneous initiation dose provides patients and care partners with the only at-home administration option throughout the Alzheimer’s disease treatment journey which could support access and delivery of care across healthcare settings. Subcutaneous administration may:

• Reduce the burden of clinic visits currently associated with anti-amyloid therapy for patients and care partners
• Reduce reliance on infusion and associated healthcare resources
• Decrease treatment preparation and administration time, and nursing monitoring requirements
• Preserve infusion capacity for patients who prefer or require intravenous therapy

Insights from an autoinjector acceptability study indicated that 94% of patients with early Alzheimer’s disease and their care partners found the LEQEMBI IQLIK device easy to use, with high levels of satisfaction and confidence in using it in an at-home setting.*

Support for Patients

The LEQEMBI Companion^TM program offers help with understanding insurance coverage and potential out-of-pocket costs, and identifying financial support programs, including the LEQEMBI Copay Assistance Program for eligible patients.

To further support access to LEQEMBI for certain patients who need help paying for their medicines, Eisai’s Patient Assistance Program (PAP) will provide LEQEMBI and LEQEMBI IQLIK at no cost, for eligible uninsured patients, who meet financial need and other program criteria.

LEQEMBI IQLIK for initiation dosing is expected to be available in late August 2026 in the U.S. Patients will receive LEQEMBI IQLIK from a specialty pharmacy.

Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

*Based on in-person interviews of 50 patients with early AD and 50 care partners currently assisting people with early AD. Participants were given the opportunity to interact with a training autoinjector device (containing no needles or medication) and an injection pad, then asked to answer computer-based surveys about their experience, including “How difficult or easy was it to use the self-injection device?”

INDICATION

LEQEMBI® is indicated for the treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

Contraindicated in patients with serious hypersensitivity to lecanemab-irmb or to any of the excipients. Reactions have included angioedema and anaphylaxis.

WARNINGS AND PRECAUTIONS

AMYLOID-RELATED IMAGING ABNORMALITIES

Medications in this class, including LEQEMBI, can cause ARIA-E, which can be observed on MRI as brain edema or sulcal effusions, and ARIA-H, which includes microhemorrhage and superficial siderosis. ARIA can occur spontaneously in patients with AD, particularly in patients with MRI findings suggestive of cerebral amyloid angiopathy (CAA), such as pretreatment microhemorrhage or superficial siderosis. ARIA-H generally occurs with ARIA-E. Reported ARIA symptoms may include headache, confusion, visual changes, dizziness, nausea, and gait difficulty. Focal neurologic deficits may also occur. Symptoms usually resolve over time.

Incidence of ARIA

Symptomatic ARIA occurred in 3% and serious ARIA symptoms in 0.7% with LEQEMBI. Clinical ARIA symptoms resolved in 79% of patients during the period of observation. ARIA, including asymptomatic radiographic events, was observed: LEQEMBI, 21%; placebo, 9%. ARIA-E was observed: LEQEMBI, 13%; placebo, 2%. ARIA-H was observed: LEQEMBI, 17%; placebo, 9%. No increase in isolated ARIA-H was observed for LEQEMBI vs placebo.

Incidence of ICH

ICH >1 cm in diameter was reported in 0.7% with LEQEMBI vs 0.1% with placebo. Fatal events of ICH in patients taking LEQEMBI have been observed.

Risk Factors of ARIA and ICH

ApoE ε4 Carrier Status

Of the patients taking LEQEMBI, 16% were ApoE ε4 homozygotes, 53% were heterozygotes, and 31% were noncarriers. With LEQEMBI, ARIA was higher in ApoE ε4 homozygotes (LEQEMBI: 45%; placebo: 22%) than in heterozygotes (LEQEMBI: 19%; placebo: 9%) and noncarriers (LEQEMBI: 13%; placebo: 4%). Symptomatic ARIA-E occurred in 9% of ApoE ε4 homozygotes vs 2% of heterozygotes and 1% of noncarriers. Serious ARIA events occurred in 3% of ApoE ε4 homozygotes and in ~1% of heterozygotes and noncarriers. The recommendations on management of ARIA do not differ between ApoE ε4 carriers and noncarriers.

Radiographic Findings of CAA

Neuroimaging findings that may indicate CAA include evidence of prior ICH, cerebral microhemorrhage, and cortical superficial siderosis. CAA has an increased risk for ICH. The presence of an ApoE ε4 allele is also associated with CAA.

The baseline presence of at least 2 microhemorrhages or the presence of at least 1 area of superficial siderosis on MRI, which may be suggestive of CAA, have been identified as risk factors for ARIA. Patients were excluded from Clarity AD for the presence of >4 microhemorrhages and additional findings suggestive of CAA (prior cerebral hemorrhage >1 cm in greatest diameter, superficial siderosis, vasogenic edema) or other lesions (aneurysm, vascular malformation) that could potentially increase the risk of ICH.

Concomitant Antithrombotic or Thrombolytic Medication

In Clarity AD, baseline use of antithrombotic medication (aspirin, other antiplatelets, or anticoagulants) was allowed if the patient was on a stable dose. Most exposures were to aspirin. Antithrombotic medications did not increase the risk of ARIA with LEQEMBI. The incidence of ICH: 0.9% in patients taking LEQEMBI with a concomitant antithrombotic medication vs 0.6% with no antithrombotic and 2.5% in patients taking LEQEMBI with an anticoagulant alone or with antiplatelet medication such as aspirin vs none in patients receiving placebo.

Fatal cerebral hemorrhage has occurred in 1 patient taking an anti-amyloid monoclonal antibody in the setting of focal neurologic symptoms of ARIA and the use of a thrombolytic agent.

Additional caution should be exercised when considering the administration of antithrombotics or a thrombolytic agent (e.g., tissue plasminogen activator) to a patient already being treated with LEQEMBI. Because ARIA-E can cause focal neurologic deficits that can mimic an ischemic stroke, treating clinicians should consider whether such symptoms could be due to ARIA-E before giving thrombolytic therapy in a patient being treated with LEQEMBI.

Caution should be exercised when considering the use of LEQEMBI in patients with factors that indicate an increased risk for ICH and, in particular, patients who need to be on anticoagulant therapy or patients with findings on MRI that are suggestive of CAA.

Radiographic Severity With LEQEMBI

Most ARIA-E radiographic events occurred within the first 7 doses, although ARIA can occur at any time, and patients can have >1 episode. Maximum radiographic severity of ARIA-E with LEQEMBI was mild in 4%, moderate in 7%, and severe in 1% of patients. Resolution on MRI occurred in 52% of ARIA-E patients by 12 weeks, 81% by 17 weeks, and 100% overall after detection. Maximum radiographic severity of ARIA-H microhemorrhage with LEQEMBI was mild in 9%, moderate in 2%, and severe in 3% of patients; superficial siderosis was mild in 4%, moderate in 1%, and severe in 0.4% of patients. With LEQEMBI, the rate of severe radiographic ARIA-E was highest in ApoE ε4 homozygotes (5%) vs heterozygotes (0.4%) or noncarriers (0%). With LEQEMBI, the rate of severe radiographic ARIA-H was highest in ApoE ε4 homozygotes (13.5%) vs heterozygotes (2.1%) or noncarriers (1.1%).

Monitoring and Dose Management Guidelines

Baseline brain MRI and periodic monitoring with MRI are recommended. Enhanced clinical vigilance for ARIA is recommended during the first 14 weeks of treatment. Depending on ARIA-E and ARIA-H clinical symptoms and radiographic severity, use clinical judgment when considering whether to continue dosing or to temporarily or permanently discontinue LEQEMBI. If a patient experiences ARIA symptoms, clinical evaluation should be performed, including MRI if indicated. If ARIA is observed on MRI, careful clinical evaluation should be performed prior to continuing treatment.

HYPERSENSITIVITY REACTIONS

Hypersensitivity reactions, including angioedema, bronchospasm, and anaphylaxis, have occurred with LEQEMBI. Promptly discontinue the infusion upon the first observation of any signs or symptoms consistent with a hypersensitivity reaction and initiate appropriate therapy.

INFUSION-RELATED REACTIONS (IRRs)

IRRs were observed—LEQEMBI: 26%; placebo: 7%—and most cases with LEQEMBI (75%) occurred with the first infusion. IRRs were mostly mild (69%) or moderate (28%). Symptoms included fever and flu-like symptoms (chills, generalized aches, feeling shaky, and joint pain), nausea, vomiting, hypotension, hypertension, and oxygen desaturation.
IRRs can occur during or after the completion of infusion. In the event of an IRR during the infusion, the infusion rate may be reduced or discontinued, and appropriate therapy initiated as clinically indicated. Consider prophylactic treatment prior to future infusions with antihistamines, acetaminophen, nonsteroidal anti-inflammatory drugs, or corticosteroids.

ADVERSE REACTIONS

• The most common adverse reactions reported in ≥5% with LEQEMBI infusion every 2 weeks and ≥2% higher than placebo were IRRs (LEQEMBI: 26%; placebo: 7%), ARIA-H (LEQEMBI: 14%; placebo: 8%), ARIA-E (LEQEMBI: 13%; placebo: 2%), headache (LEQEMBI: 11%; placebo: 8%), superficial siderosis of central nervous system (LEQEMBI: 6%; placebo: 3%), rash (LEQEMBI: 6%; placebo: 4%), and nausea/vomiting (LEQEMBI: 6%; placebo: 4%)
• The safety profile of subcutaneous LEQEMBI was similar to intravenous infusion. Subcutaneous dosing was associated with mostly localized (erythema, induration, swelling, heat, pain, pruritus, rash, ecchymosis, nodule, and hematoma) and less frequent systemic (headache, chills, fever, and fatigue) injection-related reactions, majority at first dose when initiating therapy. Localized reactions that were recurrent and/or delayed were observed. Severe localized reactions and cases leading to dose discontinuation or interruption occurred.

LEQEMBI (lecanemab-irmb) is available:

• Intravenous infusion: 100 mg/mL
• Subcutaneous injection: 200 mg/mL

Please see full Prescribing Information for LEQEMBI, including Boxed WARNING.

Click here to access the LEQEMBI digital library with assets available for download.

Notes to Editors

1.   About lecanemab (generic name, brand name: LEQEMBI^®)
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).

Lecanemab has been approved in 53 countries and regions including Japan, the United States, China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in 8 countries including the U.S., China, the UK, and others, and applications have been filed in 12 countries and regions. The U.S. FDA approved Eisai’s Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. In November 2025, an application for a subcutaneous injectable formulation in Japan was submitted. In January 2026, the Biologics License Application (BLA) for the subcutaneous formulation was accepted in China. In December 2025, lecanemab (IV) has been included in the “Commercial Insurance Innovative Drug List”, recently introduced by the National Healthcare Security Administration (NHSA) of China.

LEQEMBI’s approvals in these countries were based on Phase 3 data from Eisai’s global placebo-controlled, double-blind, parallel-group, randomized Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results. The primary endpoint was the global cognitive and functional scale, Clinical Dementia Rating Sum of Boxes (CDR-SB). Clarity AD evaluated lecanemab 10 mg/kg bi-weekly IV treatment of early Alzheimer’s disease, which involved 1,795 patients (treatment group: 898, placebo group: 897). 95% of patients who completed the core study (18 months) chose to continue in the long-term extension study (LTE), with 478 patients still receiving treatment for four years. In the Clarity AD core clinical study, data showed LEQEMBI IV significantly slowed disease progression at 18 months (27% vs placebo), and the mean change from baseline between the lecanemab treated group and the placebo group after 18 months was -0.45 (P=0.00005) on the primary endpoint of CDR-SB global cognitive and functional scale.

To provide context, a change from 0.5 to 1 on the Clinical Dementia Rating (CDR) score domains of Memory, Community Affairs and Home/Hobbies reflects a shift from mild impairment to loss of independence. This can affect a person’s ability to be left alone safely, recall recent events, participate in daily activities, manage household tasks, and engage in hobbies and intellectual interests.

LEQEMBI also rapidly reduced plaque as early as three months (−59.1 CL difference vs placebo in amyloid level at 18 months; P<0.00001).* Additionally, LEQEMBI continued to show benefit over a four-year LTE treatment period; in a subgroup analysis, 81 percent of LEQEMBI patients who stayed on treatment remained in the early AD stages at four years.**

Over three years of treatment, including both the core study and the LTE, data showed lecanemab demonstrated a reduction in cognitive decline—measured by CDR-SB—of 1.01 points compared to the expected decline observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI)** cohort. This benefit grew more pronounced after four years, with a reduction of 1.75 points. Similarly, when benchmarked against the expected decline in the BioFINDER cohort, lecanemab showed a reduction of 1.40 points at three years and an even greater reduction of 2.17 points at the four-year mark. In Clarity AD, the most common adverse events (>10%) in the lecanemab group were infusion reactions, ARIA-H (combined cerebral microhemorrhages, cerebral macrohemorrhages, and superficial siderosis), ARIA-E (edema/effusion), headache, and fall.

*The Centiloid scale is used for amyloid PET, where 0 CL is anchored as the average amyloid in young people without amyloid plaques, and 100 is anchored as the average amyloid level in moderate AD. The baseline centiloid level in CLARITY AD was approximately 78 CL. Plaque negativity is defined as conversion to amyloid PET negative (<30 centiloid, or CL). 
**Prespecified subgroup analysis of reduced risk of progression: Progression was defined as CDR-SB score progressing to moderate or severe dementia (≥9.5), based on Kaplan-Meier plots.

2.   About Protofibrils
Protofibrils are thought to be the most toxic Aβ species that contribute to brain damage in AD and play a major role in the cognitive decline of this progressive and devastating disease. Protofibrils can cause neuronal and synaptic damage in the brain, which can subsequently adversely affect cognitive function through multiple mechanisms.¹⁸The mechanism by which this occurs has been reported not only by increasing the formation of insoluble Aβ plaques, but also by directly damaging signaling between neurons and other cells. It is believed that reducing protofibrils may reduce neuronal damage and cognitive impairment, potentially preventing the progression of AD.²

3.   About the Collaboration between Eisai and Biogen for AD
Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.

4.   About the Collaboration between Eisai and BioArctic for AD
Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.

5.   About Eisai Co., Ltd.
Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.

In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.

For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.

6.   About Biogen 
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.

Biogen Safe Harbor

This news release contains forward-looking statements, including about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof including for lecanemab-irmb (LEQEMBI IQLIK); the treatment of Alzheimer’s disease; the anticipated benefits and potential of Biogen’s collaboration arrangements with Eisai; the potential of Biogen’s commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission.

These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned “Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

Digital Media Disclosure

From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors.

References

1. Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z.
2. Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer’s Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. UKNewshour.com takes no editorial responsibility for the same.

PARSIPPANY, N.J., July 13, 2026 (GLOBE NEWSWIRE) — Avis Budget Group, Inc. (NASDAQ: CAR) announced today that it plans to report its second quarter 2026 financial results after the market close on Tuesday, July 28, 2026, and to host a conference call for institutional investors to discuss these results on Wednesday, July 29, 2026, at 8:30 a.m. Eastern time.

Investors may access the call via the Company’s Investor Relations website at ir.avisbudgetgroup.com, or by dialing 877-407-2991. Investors are encouraged to dial in approximately 10 minutes prior to the start of the call.

A webcast replay will be available at ir.avisbudgetgroup.com following the call. A telephone replay will be available from 12:30 p.m. Eastern time on July 29, 2026, until 10:00 p.m. Eastern time on August 12, 2026, by dialing 877-660-6853 and using conference code 13761808.

ABOUT AVIS BUDGET GROUP

We are a leading global provider of mobility solutions through our three most recognized brands, Avis, Budget and Zipcar, as well as several other brands, well recognized in their respective markets. We license the use of the Avis, Budget, Zipcar and other brands’ trademarks to licensees in areas in which we do not operate directly. We and our licensees operate our brands in approximately 180 countries throughout the world. Our brands and mobility solutions have an extended global reach with approximately 10,000 rental locations throughout the world. We operate most of our car rental locations in North America, Europe and Australasia. We are headquartered in Parsippany, N.J. More information is available at avisbudgetgroup.com.

Investor Relations Contact:
David Calabria
IR@avisbudget.com

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. UKNewshour.com takes no editorial responsibility for the same.

In connection with the distribution, Jet.AI stockholders of record as of the close of business on July 6th, 2026, the record date for the distribution of shares of Jet.AI SpinCo, Inc. (“SpinCo”) common stock, were entitled to receive, on a pro rata basis, all outstanding shares of SpinCo, at a ratio of one share of SpinCo common stock for each share of the Company’s common stock. The distribution was completed on July 13, 2026, immediately prior to the merger. Upon completion of the merger, the SpinCo shares distributed to the Company’s stockholders converted into the right to receive the merger consideration, as described in the merger agreement for the transaction and the Company’s definitive proxy statement filed with the SEC on May 4, 2026, while retaining their existing Jet.AI shares. 

The merger consideration consists of an aggregate of 7,096,115 shares of flyExclusive Class A common stock, representing an aggregate exchange ratio of approximately 3.6253 shares of flyExclusive Class A common stock for each share of SpinCo common stock held. 5,676,892 shares of flyExclusive Class A common stock, representing approximately 80% of the merger consideration and an exchange ratio of approximately 2.9002 shares of flyExclusive Class A common stock for each share of SpinCo common stock held, were issued by flyExclusive on July 13, 2026. The remaining 1,957,402 shares of flyExclusive Class A common stock, representing approximately 20% of the merger consideration and an exchange ratio of approximately 0.7251 shares of flyExclusive Class A common stock for each share of SpinCo common stock held, are being held in reserve until the final post-closing purchase price is determined 90 days from now in accordance with the terms of the merger agreement, including any required adjustments to the purchase price. If the final purchase price is equal to or greater than the purchase price calculated at closing, the reserve shares will be issued in full by flyExclusive. If the final purchase price is less than the purchase price calculated at closing, an amount of reserve shares with a value equal to the amount of such downward adjustment will be retained by flyExclusive, and the remaining reserve shares, if any, will be issued.

About Jet.AI Inc.
Jet.AI Inc. (NASDAQ: JTAI) is a technology-driven company focused on deploying artificial intelligence tools and high-performance GPU infrastructure to enhance decision-making, efficiency, and performance across complex systems. The Company is listed on the NASDAQ Capital Market under the ticker symbol “JTAI.” To learn more, visit www.jet.ai.

Additional Information and Where to Find It
In connection with the transactions contemplated by the Amended and Restated Agreement and Plan of Merger and Reorganization, dated May 6, 2025, between Jet.AI, flyExclusive, FlyX Merger Sub, Inc., and Jet.AI SpinCo, Inc. (as amended, the “Merger Agreement”), flyExclusive has filed a Registration Statement on Form S-4 (File No. 333-284960) (as amended, the “Registration Statement”) to register the shares of flyExclusive common stock that will be issued in connection with the proposed transactions. The Registration Statement was declared effective on April 30, 2026. Jet.AI and flyExclusive filed a definitive proxy statement and final prospectus, respectively (together, the “Proxy Statement/Prospectus”), with the SEC on May 4, 2026 and they each may file with the SEC other relevant documents concerning the proposed transactions. This communication is not a substitute for the Registration Statement, the Proxy Statement/Prospectus, or any other document that the parties have filed or will file with the SEC, or send to stockholders, in connection with the proposed transactions.

This communication is not a substitute for the Registration Statement, the Proxy Statement, or any other document that the parties have filed or will file with the SEC, or send to stockholders, in connection with the proposed Transactions. Copies of the Registration Statement, Proxy Statement/Prospectus, as well as other filings containing information about the Company, may be obtained, free of charge, at the SEC’s website at www.sec.gov. You can also obtain these documents, free of charge, from the Company by accessing the Company’s website at investors.jet.ai, by directing a request to the Company at 10845 Griffith Peak Drive, Suite 200, Las Vegas, NV 89135, Attention: Board Secretary, or by phone at (702) 747-4000. The information on the Company’s website is not, and shall not be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.

No Offer or Solicitation
This communication is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. The proposed transactions are expected to be implemented solely pursuant to the legally binding definitive agreement, which contains the material terms and conditions of the proposed transactions. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended, or an exemption therefrom.

Forward-Looking Statements
This press release contains certain statements that may be deemed to be “forward-looking statements” within the meaning of the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, with respect to the products and services offered by Jet.AI and the markets in which it operates, Jet.AI’s projected future results, and Jet.AI’s perception of market conditions, including the expected timing of the closing and the future business strategy of Jet.AI. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our Company, our industry, our beliefs and our assumptions. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results, including broader market conditions. As a result, caution must be exercised in relying on forward-looking statements, which speak only as of the date they were made. Factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements can be found in the Company’s most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and Jet.AI assumes no obligation and does not intend to update or revise these forward-looking statements, whether because of new information, future events, or otherwise, except as provided by law.

Investor Relations Contact
Gateway Group, Inc.
949-574-3860
Jet.AI@gateway-grp.com

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. UKNewshour.com takes no editorial responsibility for the same.

•      Record EBITDA^{2, 3} guidance of US$167m, up 6% from the prior quarter
•      Tin production of 5,013 tonnes and 5,014 tonnes of Tin sold
•      Exploration update

Operational and Financial Summary for the Quarter ended June 2026¹

__________________________________________________________________________________________                        
¹Information is disclosed on a 100% basis. Alphamin indirectly owns 84.14% of its operating subsidiary to which the information relates.²Q2 2026 EBITDA and AISC represent management’s guidance. ³This is not a standardized financial measure and may not be comparable to similar financial measures of other issuers. See “Use of Non-IFRS Financial Measures” below for the composition and calculation of this financial measure. Apparent computational errors due to rounding are not considered significant.

Operational and Financial Performance

Contained tin production of 5,013 tonnes for the quarter ended June 2026 was in line with the target guidance of 20,000 tonnes per annum and that of the previous period. Tin sales of 5,014 tonnes were achieved compared to 5,016 in Q1 2026, resulting in the first four-quarter rolling period of 20,000 tonnes achieved. Processing recoveries dipped 2% from 74.2% in Q1 2026, to 72.8% in Q2 2026.  The metal sulphides in the current mining area are above average levels, and this resulted in excessive near gravity material interfering with the efficiency of the gravity circuit.

EBITDA for Q2 2026 is estimated at a record US$167m (Q1 2026: US$158m). The EBITDA variance compared to the prior quarter is attributable to a 5% increase in the tin price, from a US$49,278 average in Q1 2026, to US$51,957 average in Q2 2026 (current price circa US$53,000). Guidance for AISC per tonne of tin sold in Q2 2026 is estimated at US$19,043, up 6% from the previous quarter of US$17,968 due to a combination of off-mine costs in the form of increased royalties, export duties, marketing commissions and net smelter returns, which increase as tin price increases, and timing on capital expenditure. On-mine operating costs increased largely as a result of higher fuel prices impacting diesel and transport costs. Fuel stocks have been and remain at full capacity with higher prices expected to continue into Q3 due to ongoing orders at elevated prices.

Alphamin’s unaudited consolidated financial statements and accompanying Management’s Discussion and Analysis for the three and six months ended 30 June 2026 are expected to be released on or about July 31, 2026.

Exploration update

Drilling Progress

Drilling continued in Q2 2026 at Mpama North and South with mixed results;

• A total of 5,547m (Q1 2026: 4,673m) was drilled (3,654m at Mpama South; 1,893m at Mpama North).

Cassiterite (tin oxide) vein zones are associated with strong chlorite alteration. Proximity of the tin mineralisation to sulphide mineralisation has been noted whereby the sulphides tend to occur above the cassiterite zone.

Mpama North

A total of 1,893m was drilled at Mpama North in Q2, with three holes completed and a further drill hole abandoned due to difficult ground conditions.

• MND057D2_T7 Deflected from the MND057 mother hole. Intersected 1 metre of intense chlorite alteration with thin visible cassiterite mineralisation from 696m to 697m down-hole depth (approximately 610m vertical depth below surface). Although thin, this is the deepest cassiterite intersection recorded at Mpama North to date, confirming that the tin mineralising system extends to at least this depth below surface. Sampling is underway with external laboratory assay results pending.

• MND056BD4_T5 Deflected from the MND056B mother hole. Intersected 11 metres of amphibolite host rock from 609m to 620m, including 1 metre of intense chlorite alteration from 619m to 620m. No visible cassiterite mineralisation was intersected. The intersection is interpreted to be at or beyond the lateral margin of the mineralised corridor. This result informed the design of an up-dip deflection to re-test the mineralised envelope at a shallower position within the same structural corridor.

• MND057D1_T6 Deflected from the MND057 mother hole. Intersected 3.5 metres of amphibolite host rock from 702m to 705.50m with moderate chlorite alteration. No visible cassiterite mineralisation was observed, consistent with the lateral margin of the mineralised system at this depth.

Mpama South

A total of 3,653.7m was drilled at Mpama South in Q2, with 5 holes completed and a further 2 abandoned due to difficult ground conditions.

The Mpama South deposit is hosted in the same north-south trending shear zone as Mpama North, approximately 300m to the south. Q2 drilling targeted extensions of the defined resource at depth, with three of five completed holes intersecting visible cassiterite mineralisation.

• BGH206D2_T5 Visible cassiterite mineralisation observed at 19.29m, with intense chlorite and sulphide alteration from 426.41m to 445.70m. This is the most significant new intersection at Mpama South in the current programme. Two deflections from the BGH206 mother hole are planned at 275m and 230m depth to test continuity of mineralisation with the defined resource above. External laboratory assay results are pending.

• BGH204D1 Visible cassiterite mineralisation observed over 17.48m, with intense chlorite and sulphide alteration from 524.00m to 541.48m. External laboratory assay results are pending.

• BGH203D1 Visible cassiterite mineralisation observed over 1.35m, from 577.85m to 579.20m. External laboratory assay results are pending.

• BGH205D1 No visible cassiterite observed.

• BGH208A No visible cassiterite observed.

External laboratory assays on previously disclosed holes were received and included below;

• Mpama South: BGH196A_D1: 12.94m @ 2.10% Sn from 407.84m to 420.78m.

• Mpama North: MND056A_D1_T1: 0.81m @ 0.72% Sn from 567.63m to 568.44 m.

See Appendix 2 for additional assay results.

All intercepts are reported as apparent widths and true widths of the mineralisation are unknown.

Image 1: Mpama North and South cross section

Please click to view image

Future Initiatives

• Airborne Survey: A VTEM (Versatile Time Domain Electromagnetic) airborne survey covering the full Alphamin licence area was completed in mid-June 2026. Interpretation of results is underway and expected to be delivered in Q3 2026. This is intended to provide advanced targets across ABM’s license areas using the spatial association of sulphide mineralisation with cassiterite (tin oxide).

• Geochemical Surveys: Geochemical (soil) surveys commenced in Q2, to cover the Mpama Ridge north of the Oso River and all areas adjacent to basement rock units (similar geological settings to the Mpama Ridge which houses the Bisie deposit) with 13,000 samples planned for phase one of the survey which is expected to take six months to complete.

• Downhole Geophysics: A downhole electromagnetic (EM) survey tool has been mobilised to site in Q2 2026 and commenced operation in early Q3 2026. This will assist in mapping the apparent spatial association between massive sulphides and tin mineralisation in order to identify further resource extension drilling targets.

• Further Extension Drilling: Further drilling is planned to test the gap between Mpama North and Mpama South, Mpama North depth extensions beyond the current faults and north of Mpama North as depicted by the white circles in image 1.

• Resource and Reserve Update: The Company plans to release an updated resources and reserves estimate in Q4 2026.

Image 2: ABM license areas with yellow vertical lines depicting the area covered by the VTEM survey

Please click to view image

Liquidity and dividend update

The Company’s Net Cash³ position was US$91m as at 30 June 2026 (31 March 2026: US$140m) after distributions to shareholders of US$160m (US$121m to shareholders of the Company, US$26m to minority shareholders in the Company’s subsidiary in the DRC and US$13m in dividend withholding taxes in the DRC) and corporate tax payments of US$26m.

The Company intends to make a FY2026 interim dividend decision in Q4 2026.

Security and health update

The regional security situation remains largely unchanged and operations continue as normal.

In Q2 2026 an Ebola outbreak was declared in the Ituri province of Northeastern DRC. Whilst several cases have been reported in North Kivu, there have been none to date in the Walikale health zone, where the mine operates. The Company has implemented enhanced hygiene and screening protocols and expects operations to continue uninterrupted.

Qualified Person

Mr. Clive Brown, Pr. Eng., B.Sc. Engineering (Mining), is a qualified person (QP) as defined in National Instrument 43-101 and has reviewed and approved the scientific and technical information contained in this news release other than in the section “Exploration update” and Appendices 1 and 2. He is a Principal Consultant and Director of Bara Consulting Pty Limited, an independent technical consultant to the Company.

Mr. Jeremy Witley, Pr. Sci. Nat., BSc. (Hons) Mining Geology, MSc (Eng), is a qualified person (QP) as defined in National Instrument 43-101 and has reviewed and approved the scientific and technical information contained in the section “Exploration update” and Appendices 1 and 2. He is Head of Mineral Resources at the MSA Group (Pty) Ltd and is an independent technical consultant to the Company.

_________________________________________________________________________________________

FOR MORE INFORMATION, PLEASE CONTACT:

Eoin O’Driscoll                                                               
CEO                                               
Alphamin Resources Corp.                                               
Tel: +230 269 4166
E-mail: eoin.odriscoll@alphaminresources.com

CAUTION REGARDING FORWARD LOOKING STATEMENTS

Information in this news release that is not a statement of historical fact constitutes forward-looking information. Forward-looking statements contained herein include, without limitation, statements relating to EBITDA and AISC guidance and constituent components of AISC for Q2 2026; guidance for contained tin production for the year ending 31 December 2026; the expected timing regarding the next dividend assessment; expected timing for the release of financial results for the three and six months ended 30 June 2026, the expectation that higher fuel prices will negatively affect financial results for Q3 2026; anticipated future exploration activities; expected timing for updating the Company’s mineral resources and mineral reserves; and expectations regarding the effects on operations of the recent Ebola outbreak in North Eastern DRC. Forward-looking statements are based on assumptions management believes to be reasonable at the time such statements are made. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Although Alphamin has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Factors that may cause actual results to differ materially from expected results described in forward-looking statements include, but are not limited to: the availability of ore at expected quantities and grades, uninterrupted processing of ore at targeted processing recoveries, uncertainties regarding global supply and demand for tin and market and sales prices together with the impact of reported and unreported global tin stocks on the tin price, uncertainties with respect to social, community, environmental and safety impacts, uninterrupted access to required infrastructure and third party service providers, uncertainties regarding the state of inbound and outbound roads and truck availabilities impacting sales and the availability of spares and consumables, adverse political events and risks of security related incidents or security threats which may impact the ongoing operation or safety of its people, uncertainties regarding the legislative and permitting requirements in the Democratic Republic of the Congo which may result in unexpected fines and penalties or the ability to continue with normal operations, impacts of the global Covid-19 pandemic or other health crises, including the Bundibugyo Ebola outbreak, on mining operations and commodity prices as well as those risk factors set out in the Company’s most recent annual Management Discussion and Analysis and other disclosure documents available under the Company’s profile at www.sedarplus.ca. Forward-looking statements contained herein are made as of the date of this news release and Alphamin disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

USE OF NON-IFRS FINANCIAL PERFORMANCE MEASURES

This announcement refers to the following non-IFRS financial performance measures:

EBITDA

EBITDA is profit before net finance expense, income taxes and depreciation, depletion, and amortization. EBITDA provides insight into our overall business performance (a combination of cost management and growth) and is the corresponding flow driver towards the objective of achieving industry-leading returns. This measure assists readers in understanding the ongoing cash generating potential of the business including liquidity to fund working capital, servicing debt, and funding capital and exploration expenditures and investment opportunities.

This measure is not recognized under IFRS as it does not have any standardized meaning prescribed by IFRS and is therefore unlikely to be comparable to similar measures presented by other issuers. EBITDA data is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS.

CASH COSTS

This measures the cash costs to produce and sell a tonne of contained tin. This measure includes mine operating production expenses such as mining, processing, administration, indirect charges (including surface maintenance and camp and head office costs), and smelting, refining and freight, distribution and royalties. Cash costs do not include depreciation, depletion, and amortization, reclamation expenses, capital sustaining, borrowing costs and exploration expenses. On-mine costs, exclusive of stock movement, are calculated on a cost per tonne produced basis, off-mine costs are calculated on a cost per tonne sold basis.

AISC

This measures the cash costs to produce and sell a tonne of contained tin plus the capital sustaining costs to maintain the mine, processing plant and infrastructure. This measure includes the Cash Cost per tonne and capital sustaining costs together divided by tonnes of contained tin produced. All-In Sustaining Cost per tonne does not include depreciation, depletion, and amortization, reclamation, borrowing costs, foreign exchange gains and losses, exploration expenses and expansion capital expenditures.

Sustaining capital expenditures are defined as those expenditures which do not increase payable mineral production at a mine site and excludes all expenditures at the Company’s projects and certain expenditures at the Company’s operating sites which are deemed expansionary in nature.

Net Cash/Debt
Net cash/(debt) demonstrates how our net cash/(debt) is being managed and is defined as net cash and cash equivalents less total current and non-current portions of debt and lease liabilities.

Appendix 1: SAMPLE PREPARATION, ANALYSES AND QUALITY CONTROL AND QUALITY ASSURANCE (QAQC)

Mpama North and Mpama South diamond drilling was completed from surface. The collar positions of the drillholes were accurately surveyed by Alphamin Bisie Mining (ABM) and down-hole surveys were completed by the drilling contractor allowing for accurate location of the mineralised intercepts.  Cores were logged, mineralised intervals were identified and half core samples were taken at nominal 1 m intervals by the ABM geologists, which included the insertion of various certified reference material and blank samples (QAQC). No significant issues with the QAQC samples were noted. At the on-site ABM laboratory (managed by Anchem), samples were first checked off against the submission list supplied and then weighed and oven dried for 2 hours at 105 degrees Celsius. The dried samples were crushed by jaw crusher to 75% passing 2mm, from which a 250g riffle split was taken. This 250g split was pulverised in ring mills to 90% passing 75μm from which a sample for analysis was taken.  Received samples at ALS Johannesburg are checked off against the list of samples supplied and logged in the system. Quality Control is performed by way of sieve tests every 50 samples and should a sample fail, the preceding 50 samples are ground in a ring mill pulveriser using a carbon steel ring set to 85 % passing 75μm. Samples are analysed for tin using method code ME-XRF05 conducted on a pressed pellet with 10% precision and an upper limit of 5,000ppm. The over-limit tin samples are analysed as fused disks according to method ME-XRF15c, which makes use of pre-oxidation and decomposition by fusion with 12:22 lithium borate flux containing 20% Sodium Nitrate as an oxidizing agent, with an upper detection limit of 79% Sn.

Appendix 2: SIGNIFICANT INTERCEPTS (0.5% Sn lower threshold)
Mpama South Drillholes prefixed “BGH”

Mpama North Drillholes prefixed “MNUD” and “MND”

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. UKNewshour.com takes no editorial responsibility for the same.

The proposed transaction values Vita at a pre-money enterprise value of $450 million, assuming Vita successfully completes its pending strategic acquisition within the defense and industrials market. The announcement reflects Vita’s continued momentum and represents an important step in the company’s evolution as it prepares for its next phase of growth.

In connection with executing the LOI, Tavia and Vita are engaged in a series of initial non-binding investment indications of from institutional investors and certain strategic partners. Firm commitments from those investors, as well as any other investors, would be announced concurrently with the signing of a definitive agreement.

Tavia expects to announce additional details regarding the proposed business combination when a definitive agreement is executed, which is expected within the next thirty days and with a closing anticipated in the fourth quarter of 2026.

Caleb Carr, Chief Executive Officer of Vita Inclinata Technologies, said:

“This is an important step for Vita and reflects the progress our team has made in building a differentiated business. We believe access to the public markets will strengthen our ability to invest in innovation, expand our portfolio of products and solutions, pursue new opportunities, and create long-term value for our customers and shareholders.”

Kanat Mynzhanov, Chief Executive Officer / Chairman of Tavia Acquisition Corp., said:

“Vita has built a distinctive business with innovative products, disciplined execution, and a compelling vision for the future. We believe the company is well positioned for its next stage of growth, and we look forward to advancing this opportunity together.”

About Vita Inclinata Technologies

Vita Inclinata Technologies develops innovative products and solutions designed to improve safety, precision, and operational performance in demanding environments. Through engineering expertise, operational excellence, and a customer-focused approach, the company continues to expand its portfolio while delivering meaningful value to customers.

About Tavia Acquisition Corp.

Tavia Acquisition Corp. (Nasdaq: TAVI) is a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

Letter of Intent

The LOI is non-binding and subject to the execution of definitive agreements, completion of due diligence, required approvals and customary closing conditions. No assurances can be made that the parties will successfully negotiate and enter into a definitive agreement, or that the proposed transaction will be consummated on the terms or timeframe currently contemplated, or at all.

Exclusivity

The parties have agreed to a 45-day exclusivity period to undertake due diligence and negotiate a definitive Business Combination Agreement.

Advisors

Cohen & Company Capital Markets, a division of Cohen & Company Securities, LLC, is acting as lead financial advisor and capital markets advisor to Tavia and EarlyBirdCapital is acting as capital markets advisor to Tavia. Greenberg Traurig LLP is serving as legal counsel to Vita. Reed Smith LLP is serving as legal counsel to Tavia.

Additional Information and Where to Find It

If a definitive agreement is entered into in connection with the proposed business combination, a newly formed holding company, Vita or Tavia will prepare a registration statement, including a proxy statement/prospectus, to be filed with the U.S. Securities and Exchange Commission (“SEC”). The proxy statement/prospectus will be mailed to Tavia’s shareholders. Tavia urges investors and other interested persons to read, when available, the proxy statement/prospectus, as well as other documents filed with the SEC, because these documents will contain important information about the proposed business combination. Such persons can also read Tavia’s filings with the SEC for a description of the security holdings of its officers and directors and their respective interests as security holders in the consummation of the transactions described herein. The proxy statement statement/prospectus, once available, can be obtained, without charge, at the SEC’s web site (http://www.sec.gov).

Participants in the Solicitation

Vita and Tavia and their respective directors, executive officers and other members of their management and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of Tavia’s shareholders in connection with the proposed business combination. Investors and security holders may obtain more detailed information regarding the names, affiliations and interests of Tavia’s directors and officers in Tavia’s SEC filings. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to Tavia’s shareholders in connection with the proposed business combination will be set forth in the proxy statement/prospectus for the proposed business combination when available. Information concerning the interests of Vita’s and Tavia’s participants in the solicitation, which may, in some cases, be different than those of their respective equity holders generally, will be set forth in the proxy statement/prospectus relating to the proposed business combination when it becomes available.

Forward-Looking Statements

This press release contains certain statements that are not historical facts and are forward-looking statements within the meaning of the federal securities laws with respect to the potential business combination between Tavia and Vita. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “think,” “strategy,” “future,” “opportunity,” “potential,” “plan,” “seeks,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.

These factors include, but are not limited to, whether a definitive agreement for the proposed business combination transaction will be entered into; whether such business combination transaction, or any other contemplated transaction, may be completed with different terms, in an untimely manner, or not at all; whether the parties will be able to realize the benefits of the proposed business combination transaction described herein; market and other conditions. The parties do not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Tavia’s Annual Report on Form 10-K and periodic reports filed with the SEC.  All of Tavia’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof, and the parties assume no obligation to update or revise these statements unless otherwise required by law.

No Offer or Solicitation

This press release is not a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the potential business combination and will not constitute an offer to sell or the solicitation of an offer to buy or exchange any securities, nor will there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Contact Information:

info@tavia.co

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. UKNewshour.com takes no editorial responsibility for the same.

Under the terms of the securities purchase agreement, the Company has agreed to sell to certain investors an aggregate of approximately $4 million of the Company’s securities, including 10,000,000 Class A ordinary shares (the “Shares”) (or pre-funded warrants in lieu thereof), at an offering price of $0.40 per share in the Offering. The purchase price for the pre-funded warrants is identical to the purchase price for Shares, less the exercise price of $0.33 per share.

The aggregate gross proceeds to the Company were $4 million.

Univest Securities, LLC acted as the sole placement agent.

The registered direct offering was made pursuant to a shelf registration statement on Form F-3 (File No. 333-287686) previously filed by the Company and declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on June 13, 2025. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering were filed with the SEC and are available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, by contacting Univest Securities, LLC at info@univest.us, or by calling +1 (212) 343-8888.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Copies of the prospectus supplement relating to the registered direct offering, together with the accompanying base prospectus, can be obtained at the SEC’s website at www.sec.gov.

About Univest Securities, LLC

Registered with FINRA since 1994, Univest Securities, LLC provides a wide variety of financial services to its institutional and retail clients globally, including brokerage and execution services, sales and trading, market making, investment banking and advisory, and wealth management. It strives to provide clients with value-added service and focuses on building long-term relationships with its clients. As a prominent name on Wall Street, Univest has successfully raised over $1.8 billion in capital for issuers across the globe since 2019 and has completed approximately 100 transactions spanning a wide array of investment banking services in various industries, including technology, life sciences, industrial, consumer goods, etc. For more information, please visit: www.univest.us.

About Haoxi Health Technology Ltd

Haoxi Health Technology Limited is a Beijing-headquartered online marketing solution provider in China, specializing in serving healthcare industry advertiser clients. The Company’s growth is driven by the rise of news feed ads and the rapid development of the healthcare sector. The Company offers one-stop online marketing solutions, especially in online short video marketing, helping advertisers acquire and retain customers on popular platforms in China, such as Toutiao, Douyin, WeChat, and Sina Weibo. It is dedicated to reducing costs, increasing efficiency, and providing easy online marketing solutions to advertisers. For more information, please visit: https://ir.haoximedia.com/.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks, including, but not limited to, the uncertainties related to market conditions and the completion of the initial public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. Univest Securities LLC and the Company undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

Univest Securities, LLC
Edric Guo
Chief Executive Officer
75 Rockefeller Plaza, Suite 25A
New York, NY 10019
Phone: (212) 343-8888
Email: info@univest.us

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. UKNewshour.com takes no editorial responsibility for the same.

If you purchased or acquired Peabody Energy common stock between October 14, 2024 to May 4, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.

Click here to participate in the action.

NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) —

What’s Happening?

• Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Peabody Energy Corporation (“Peabody Energy” or the “Company”) (NYSE:BTU) in the United States District Court for the Eastern District of Missouri on behalf of all persons and entities who purchased or otherwise acquired Peabody Energy common stock between October 14, 2024 to May 4, 2026, both dates inclusive (the “Class Period”). Investors have until August 24, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Allegation Details:

• According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Peabody Energy’s Centurion mine and the multitude of issues causing delays to the ramp-up and the return to full longwall production dates. On March 30, 2026, Peabody Energy issued a press release lowering guidance pertaining to Centurion mine’s expected first quarter 2026 output ahead of the Company’s full earnings release. In pertinent part, defendants announced that sales volume from the Centurion mine was expected to deliver approximately 250,000 tons in the first quarter due to mining commissioning challenges (compared to previous estimates of around 700,000 tons). Following this news, the price of Peabody Energy’s common stock declined dramatically. From a closing market price of $39.50 per share on March 27, 2026, Peabody Energy’s stock price fell to $35.68 per share on March 30, 2026, a decline of about 9.7% in the span of a single trading day.
• On May 5, 2026, Peabody Energy issued a press release disclosing the Company’s failure to ramp-up Centurion by the long-awaited March 2026 deadline and cutting guidance related to full year met segment volumes to reflect the increased cost and substantial volume decrease. Following this news, Peabody Energy’s common stock declined from a closing market price of $26.52 per share on May 4, 2026, to $25.00 per share on May 5, 2025, a decline of 5.7%.

Next Steps:

• If you purchased or otherwise acquired Peabody Energy shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities,
derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com.  Attorney advertising.  Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. UKNewshour.com takes no editorial responsibility for the same.